Chronicare Leadership

The Chronicare leadership team encompasses great depth and breadth in commercial, product development and clinical and medical affairs in life sciences and medical devices, and more specifically, in diabetes medical device products and services.

Dave Walton CEO

David Walton

Founder & CEO

Dave Walton currently serves as CEO and founder of Chronicare. Dave has spent 23 years in the healthcare industry in a variety of strategy and commercial roles, with the last 12 years focused on the diabetes industry.

Dave served as the Chief Commercial Officer at AgaMatrix, a privately-held glucose monitoring and digital health company. Prior to AgaMatrix, he was VP of Marketing and Commercial Development at Echo Therapeutics, a company developing a non-invasive continuous glucose monitoring system for the hospital setting. Prior to Echo, Dave spent six years at J&J at Animas / LifeScan in marketing and strategy roles, where he led the commercial launch of Animas Vibe, an insulin pump and continuous glucose monitoring system, as well as other insulin pump & glucose monitoring systems and web-based reporting products. He spent another five years at J&J in strategic marketing at two separate pharmaceutical divisions.

He also spent six years in management consulting serving pharmaceutical, medical device, health plan and integrated delivery system clients on various strategy and operational improvement projects.

Dave earned his BA in Psychology from Princeton University and his MBA in Healthcare Management from the Wharton School at the University of Pennsylvania.

VP of R&D

Tom Bishop

VP of R&D

Tom Bishop serves as Vice President of Research and Development for Chronicare. Mr. Bishop is an expert in medical device development and has over 30 years of experience leading the R&D of innovative products for the medical device, networking and military industries. Prior to joining Chronicare, Mr. Bishop consulted with several med tech startup companies, including managing all business-development activities for DirectSens, a manufacturer of 3rd generation enzymes for advanced glucose monitors. For three years, Mr. Bishop was the Vice President for Product Development for Echo Therapeutics where he led development of a novel, non-invasive continuous glucose monitoring system. Mr. Bishop also holds several patents and has in-depth expertise in glucose monitoring.

Prior to Echo, Mr. Bishop served as Vice President of Engineering for TransMedics, where he led the development of revolutionary devices that maintained human hearts and lungs in a functioning state outside of the body. During his eight years with TransMedics, Mr. Bishop led commercialization projects that resulted in product introductions in both the EU and USA. Prior to TransMedics, Mr. Bishop spent 10 years with Siemens Medical Systems where he managed the development of 3 generations of ICU Patient Monitors. Mr. Bishop also held a leadership position with Analogic Corporation.

Tom earned his BA in Computer Science and Economics from Denison University.